Gilead

Nachrichten

Reuters - vor 5 Tagen

Trodelvy Continues To Show Durable Overall Survival Advantage In Pre-Treated Hr+/Her2- Metastatic Breast Cancer

BRIEF-Trodelvy Continues To Show Durable Overall Survival Advantage In Pre-Treated Hr+/Her2- Metastatic Breast Cancer June 5 (Reuters) - Gilead Sciences Inc GILD.O : TRODELVY® CONTINUES TO SHOW DURABLE OVERALL SURVIVAL ADVANTAGE IN PRE-TREATED HR+/HER2- METASTATIC BREAST CANCER GILEAD SCIENCES INC - OVERALL SURVIVAL BENEFIT OBSERVED WITH TRODELVY IN PATIENTS WITH HER2-LOW (IHC 1+, IHC2+/ISH-) AND HER2-IHC0 STATUS GILEAD SCIENCES- TRODELVY SHOWS MEANINGFUL 3.3 MONTH IMPROVEMENT IN MEDIAN OVERALL

Reuters - vor 5 Tagen

Kite's Yescarta Car T-Cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard Of Care As Initial Treatment Of Relapsed/Refractory Large B-Cell Lymphoma

BRIEF-Kite's Yescarta Car T-Cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard Of Care As Initial Treatment Of Relapsed/Refractory Large B-Cell Lymphoma June 5 (Reuters) - Kite: KITE'S YESCARTA® CAR T-CELL THERAPY DEMONSTRATES SIGNIFICANTLY LONGER OVERALL SURVIVAL VERSUS STANDARD OF CARE AS INITIAL TREATMENT OF RELAPSE

Reuters - vor 5 Tagen

Cancer drugmakers rise as industry meet fuels investor interest

UPDATE 1-Cancer drugmakers rise as industry meet fuels investor interest Adds analysts' comments in paragraphs 4 and 9, G1 Therapeutics in paragraph 7, Blueprint Medicines in paragraph 9, updates share movement June 5 (Reuters) - Shares of several cancer drug firms surged on Monday after the companies reported positive clinical trial data from their therapies at an ongoing industry conference in Chicago.

Reuters - vor 5 Tagen

Cancer drugmakers rise as industry meet fuels investor interest

Cancer drugmakers rise as industry meet fuels investor interest June 5 (Reuters) - Shares of several cancer drug firms surged in premarket trading on Monday after the companies reported positive clinical trial data from their therapies at an ongoing industry conference in Chicago. Day One Bio DAWN.O , Immunogen Inc IMGN.O and Evaxion Biotech A/S EVAX.O were among the biggest sector gainers after presentations at the annual American Society of Clinical Oncology (ASCO) meeting.

Reuters - vor 1 Woche

Gilead Announce Anti-Tigit Domvanalimab Continues To Demonstrate Consistent Improvement In Progression-Free Survival In Non-Small Cell Lung Cancer Study

BRIEF-Gilead Announce Anti-Tigit Domvanalimab Continues To Demonstrate Consistent Improvement In Progression-Free Survival In Non-Small Cell Lung Cancer Study June 3 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD AND ARCUS ANNOUNCE ANTI-TIGIT DOMVANALIMAB CONTINUES TO DEMONSTRATE CONSISTENT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN NON-SMALL CEL

Reuters - vor 3 Wochen

Former Immunomedics CFO pleads guilty to insider trading

Former Immunomedics CFO pleads guilty to insider trading By Jonathan Stempel May 17 (Reuters) - The former chief financial officer of a New Jersey biotechnology company pleaded guilty on Wednesday to insider trading, after prosecutors said he had given nonpublic information about a new breast cancer drug to his girlfriend at the time. Usama Malik, 48, former CFO of Immunomedics Inc, now owned by Gilead Sciences Inc GILD.O , admitted to a single charge of securities fraud at a hearing before U.S.

Reuters - vor 4 Wochen

Gilead Appoints Cindy Perettie Executive Vice President Of Kite

BRIEF-Gilead Appoints Cindy Perettie Executive Vice President Of Kite Gilead Sciences Inc GILD.O : GILEAD APPOINTS CINDY PERETTIE EXECUTIVE VICE PRESIDENT OF KITE Source text for Eikon: ID:nBw6w9n7pa Further company coverage: GILD.O

Reuters - vor 4 Wochen

Gilead Sciences And Arcus Biosciences Expand Partnership To Include Research Programs In Inflammation

BRIEF-Gilead Sciences And Arcus Biosciences Expand Partnership To Include Research Programs In Inflammation Gilead Sciences Inc GILD.O : GILEAD SCIENCES AND ARCUS BIOSCIENCES EXPAND PARTNERSHIP TO INCLUDE RESEARCH PROGRAMS IN INFLAMMATION ARCUS BIOSCIENCES INC - GILEAD TO HAVE EARLY OPTION TO EXCLUSIVELY LICENSE DRUG CANDIDATES AGAINST UP TO FOUR T

Reuters - vor 4 Wochen

Germany's Merck flags decline in operating profit of up to 10% in 2023

CORRECTED-UPDATE 1-Germany's Merck flags decline in operating profit of up to 10% in 2023 Corrects percentage of profit decline in 5th paragraph to 2.6%, not 7% By Ludwig Burger FRANKFURT, May 11 (Reuters) - Germany's Merck KGaA MRCG.DE on Thursday warned that adjusted operating earnings could decline by as much as 10% this year as the outlook for its specialty chemicals business darkened, offsetting an upswing in drug prescriptions.

Reuters - vor 1 Monat

Gilead Sciences prevails in US government lawsuit over HIV drug patents

UPDATE 1-Gilead Sciences prevails in US government lawsuit over HIV drug patents Adds trial detail in paragraph 2, request for U.S. comment in paragraph 6, share move in paragraph 8 By Blake Brittain May 9 (Reuters) - A federal jury on Tuesday found that Gilead Sciences Inc GILD.O did not infringe U.S. patents with its HIV-prevention regimens using the drugs Truvada and Descovy, handing the government a defeat in its billion-dollar lawsuit.

Reuters - vor 1 Monat

Gilead Sciences prevails in US government lawsuit over HIV drug patents

Gilead Sciences prevails in US government lawsuit over HIV drug patents By Blake Brittain May 9 (Reuters) - A federal jury on Tuesday found that Gilead Sciences Inc GILD.O did not infringe U.S. patents with its HIV-prevention regimen using the drugs Truvada and Descovy, handing the government a defeat in its billion-dollar lawsuit. The Delaware jury found the government's patents were invalid and not infringed.

Reuters - vor 1 Monat

Gilead Strengthens Early Pipeline In Oncology And Inflammation Through Acquisition Of Xinthera

BRIEF-Gilead Strengthens Early Pipeline In Oncology And Inflammation Through Acquisition Of Xinthera May 9 (Reuters) - Gilead Sciences Inc GILD.O : GILEAD STRENGTHENS EARLY PIPELINE IN ONCOLOGY AND INFLAMMATION THROUGH THE ACQUISITION OF XINTHERA GILEAD SCIENCES INC - FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED GILEAD - EXPECT DEAL WITH XINTHER

Reuters - vor 1 Monat

CHMP Adopts Positive Opinion Recommending Hepcludex(Bulevirtide) For Full Marketing Authorization For The Treatment Of Hepatitis Delta Virus (Hdv)

BRIEF-CHMP Adopts Positive Opinion Recommending Hepcludex(Bulevirtide) For Full Marketing Authorization For The Treatment Of Hepatitis Delta Virus (Hdv) May 4 (Reuters) - Gilead Sciences Inc GILD.O : CHMP ADOPTS POSITIVE OPINION RECOMMENDING HEPCLUDEX® (BULEVIRTIDE) FOR FULL MARKETING AUTHORIZATION FOR THE TREATMENT OF HEPATITIS DELTA VIRUS (HDV)

Reuters - vor 1 Monat

Gilead, US square off in billion-dollar HIV drug patent trial

Gilead, US square off in billion-dollar HIV drug patent trial By Blake Brittain May 2 (Reuters) - Gilead Sciences Inc GILD.O is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen. The government is seeking more than $1 billion from Gilead for allegedly failing to compensate the Centers for Disease Control and Prevention (CDC) for discovering that Gilead's HIV-treatment dr

Reuters - vor 1 Monat

Drugmakers scout for deals, ramp up research spending

WRAPUP 3-Drugmakers scout for deals, ramp up research spending Adds analyst comments, Amgen and Gilead earnings; updates shares By Manas Mishra and Patrick Wingrove April 27 (Reuters) - Drugmakers including Merck & Co MRK.N , AstraZeneca Plc AZN.L and AbbVie Inc ABBV.N said on Thursday they are open to acquisitions and reported a ramp up in research and development spending as the industry's larger players look for new sources of future revenue.

Reuters - vor 1 Monat

Gilead profit misses Wall Street expectations as COVID drug sales decline

UPDATE 1-Gilead profit misses Wall Street expectations as COVID drug sales decline Adds sales details, share move, full-year forecast April 27 (Reuters) - Gilead Sciences Inc GILD.O on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%.

Reuters - vor 1 Monat

Gilead profit misses Wall Street expectations as COVID drug sales decline

Gilead profit misses Wall Street expectations as COVID drug sales decline April 27 (Reuters) - Gilead Sciences Inc GILD.O on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated. Sales of the drug decreased by 63% to $573 million for the quarter, well off analysts' estimates of $697.6 million.

Reuters - vor 1 Monat

Gilead Sciences Qtrly Adj. EPS $1.37

BRIEF-Gilead Sciences Qtrly Adj. EPS $1.37 April 27 (Reuters) - Gilead Sciences Inc GILD.O : QTRLY PRODUCT SALES EXCLUDING VEKLURY INCREASED 15% Y-O-Y TO $5.7 BILLION QTRLY REVENUE $6.4 BILLION VERSUS ESTIMATE $6.33 BILLION QTRLY BIKTARVY SALES INCREASED 24% T-O-Y TO $2.7 BILLION QTRLY EARNINGS PER SHARE $0.80 QTRLY ADJUSTED EARNINGS PER SHARE $1.37 VERSUS ESTIMATE $1.54 DURING Q1, CO PAID DIVIDENDS OF $969 MILLION AND REPURCHASED $400 MILLION OF COMMON STOCK QTRLY TOTAL PRODUCT SALES $6.3 BILLI

Reuters - vor 1 Monat

Fresh spur from Meta and Europe's banks

MORNING BID AMERICAS-Fresh spur from Meta and Europe's banks A look at the day ahead in U.S. and global markets from Mike Dolan The Big Tech earnings season is going some way to justifying the striking outperformance of its mega cap shares this year, with Meta Platforms METAO. the latest to impress overnight and Amazon AMZN.O advancing ahead of its readout on Thursday.

Reuters - vor 2 Monaten

Canada, Volkswagen to invest more than C$20 bln in EV battery gigafactory

UPDATE 2-Canada, Volkswagen to invest more than C$20 bln in EV battery gigafactory Adds comments from St. Thomas mayor, Volkswagen battery unit CEO By Steve Scherer and Victoria Waldersee OTTAWA, April 21 (Reuters) - Canada and Volkswagen VOWG_p.DE on Friday together committed more than C$20 billion ($14.8 billion) for a battery gigafactory in St.

Konditionen

Beliebte Finanzwerte

Rechtlicher Hinweis: Die Unternehmen der XM Group bieten Dienstleistungen ausschließlich zur Ausführung an sowie Zugang zu unserer Online-Handelsplattform. Durch diese können Personen die verfügbaren Inhalte auf oder über die Internetseite betrachten und/oder nutzen. Eine Änderung oder Erweiterung dieser Regelung ist nicht vorgesehen und findet nicht statt. Der Zugang wird stets geregelt durch folgende Vorschriften: (i) Allgemeine Geschäftsbedingungen; (ii) Risikowarnungen und (iii) Vollständiger rechtlicher Hinweis. Die bereitgestellten Inhalte sind somit lediglich als allgemeine Informationen zu verstehen. Bitte beachten Sie, dass die Inhalte auf unserer Online-Handelsplattform keine Aufforderung und kein Angebot zum Abschluss von Transaktionen auf den Finanzmärkten darstellen. Der Handel auf Finanzmärkten birgt ein hohes Risiko für Ihr eingesetztes Kapital.

Sämtliche Materialien, die auf unserer Online-Handelsplattform veröffentlicht sind, dienen ausschließlich dem Zweck der Weiterbildung und Information. Die Materialien beinhalten keine Beratung und Empfehlung im Hinblick auf Finanzen, Anlagesteuer oder Handel und sollten nicht als eine dahingehende Beratung und Empfehlung aufgefasst werden. Zudem enthalten die Materialien keine Aufzeichnungen unserer Handelspreise sowie kein Angebot und keine Aufforderung für jegliche Transaktionen mit Finanzinstrumenten oder unverlangte Werbemaßnahmen für Sie zum Thema Finanzen. Die Materialien sollten auch nicht dahingehend aufgefasst werden.

Alle Inhalte von Dritten und die von XM bereitgestellten Inhalte sowie die auf dieser Internetseite zur Verfügung gestellten Meinungen, Nachrichten, Forschungsergebnisse, Analysen, Kurse, sonstigen Informationen oder Links zu Seiten von Dritten werden ohne Gewähr bereitgestellt. Sie sind als allgemeine Kommentare zum Marktgeschehen zu verstehen und stellen keine Anlageberatung dar. Soweit ein Inhalt als Anlageforschung aufgefasst wird, müssen Sie beachten und akzeptieren, dass der Inhalt nicht in Übereinstimmung mit gesetzlichen Bestimmungen zur Förderung der Unabhängigkeit der Anlageforschung erstellt wurde. Somit ist der Inhalt als Werbemitteilung unter Beachtung der geltenden Gesetze und Vorschriften anzusehen. Bitte stellen Sie sicher, dass Sie unseren Hinweis auf die nicht unabhängige Anlageforschung und die Risikowarnung im Hinblick auf die vorstehenden Informationen gelesen und zur Kenntnis genommen haben, die Sie hier finden.

Gilead

Nachrichten

Konditionen

Beliebte Finanzwerte

XM Live-Chat